H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating
Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics ACTU.O with "buy" rating
Brokerage sets PT at $20, representing more than 100% upside to the stock's last close
In a mid-stage study, co's experimental therapy for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death
Brokerage says the trial data for the therapy, elraglusib, "positions it as a frontrunner among competition" for pancreatic cancer treatments
Brokerage is optimistic about ACTU because the pancreatic cancer market has a significant unmet need
Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033
ACTU has fallen 8.9% YTD
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
